Literature DB >> 3279027

Functional and structural similarities between protease nexin I and C1 inhibitor.

W E Van Nostrand1, L D McKay, J B Baker, D D Cunningham.   

Abstract

Protease nexin I is a proteinase inhibitor that is secreted by human fibroblasts and forms stable complexes with certain serine proteinases; the complexes then bind to the fibroblasts and are rapidly internalized and degraded. In this report, we show that this inhibitor, which is present in very low concentrations in plasma, has functional and structural similarities to C1 inhibitor, an abundant proteinase inhibitor in plasma. Both inhibitors complex and inactivate certain proteinases that previously were known to rapidly react only with C1 inhibitor. Kinetic inhibition studies show that protease nexin I inhibits Factor XIIa and plasma kallikrein with second-order rate constants of 2.3 x 10(3) and 2.5 x 10(5) M-1 s-1, respectively, which are similar to the rate constants for inhibition of these proteinases by C1 inhibitor. Protease nexin I inhibits C1s about one-tenth as rapidly as does C1 inhibitor. Alignment of the amino acid sequences of protease nexin I and C1 inhibitor shows that these proteins have similarity at their reactive centers (from sites P7 to P1). The remaining regions of the two proteins share much less similarity. In contrast to protease nexin I, C1 inhibitor is not secreted by human fibroblasts. Although 125I-C1s-protease nexin I complexes readily bind to human fibroblasts, binding of 125I-C1s-C1 inhibitor complexes or other 125I-proteinase-C1-inhibitor complexes to these cells is not detectable. Thus, protease nexin I and C1 inhibitor may control some common regulatory proteinases in the extravascular and vascular compartments, respectively.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3279027

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  6 in total

1.  Alterations of coagulation and fibrinolysis in patients with angioedema due to C1-inhibitor deficiency.

Authors:  M van Geffen; M Cugno; P Lap; A Loof; M Cicardi; W van Heerde
Journal:  Clin Exp Immunol       Date:  2012-03       Impact factor: 4.330

Review 2.  Complement in the brain.

Authors:  Robert Veerhuis; Henrietta M Nielsen; Andrea J Tenner
Journal:  Mol Immunol       Date:  2011-05-04       Impact factor: 4.407

3.  Complement activation in amyloid plaques in Alzheimer's disease brains does not proceed further than C3.

Authors:  R Veerhuis; P van der Valk; I Janssen; S S Zhan; W E Van Nostrand; P Eikelenboom
Journal:  Virchows Arch       Date:  1995       Impact factor: 4.064

4.  Patterns of C1-Inhibitor/Plasma Serine Protease Complexes in Healthy Humans and in Hereditary Angioedema Patients.

Authors:  Erika Kajdácsi; Zsófia Jandrasics; Nóra Veszeli; Veronika Makó; Anna Koncz; Dominik Gulyás; Kinga Viktória Köhalmi; György Temesszentandrási; László Cervenak; Péter Gál; József Dobó; Steven de Maat; Coen Maas; Henriette Farkas; Lilian Varga
Journal:  Front Immunol       Date:  2020-05-05       Impact factor: 7.561

Review 5.  Anticoagulant SERPINs: Endogenous Regulators of Hemostasis and Thrombosis.

Authors:  Steven P Grover; Nigel Mackman
Journal:  Front Cardiovasc Med       Date:  2022-05-03

6.  Serine protease HtrA1 accumulates in corneal transforming growth factor beta induced protein (TGFBIp) amyloid deposits.

Authors:  Henrik Karring; Ebbe Toftgaard Poulsen; Kasper Runager; Ida B Thøgersen; Gordon K Klintworth; Peter Højrup; Jan J Enghild
Journal:  Mol Vis       Date:  2013-04-12       Impact factor: 2.367

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.